Pharmaceutical care for a Crohn's disease patient with hypoalbuminemia and non-response to infliximab
10.12206/j.issn.2097-2024.202102009
- VernacularTitle:克罗恩病合并低蛋白血症患者对英夫利昔单抗失应答的用药分析与监护
- Author:
Tingting LIN
1
;
Tingting ZENG
2
;
Jing TIAN
3
Author Information
1. Changhai Hospital, Naval Medical University, Shanghai 200433, China;Hospital Affiliated to Binzhou Medical University Hospital, Binzhou 256603, China.
2. Tianjin Rehabilitation and Convalescent Center of Joint Logistic Support Force of the PLA, Tianjin 300381, China.
3. Changhai Hospital, Naval Medical University, Shanghai 200433, China.
- Keywords:
Crohn’s disease;
infliximab;
therapeutic drug monitoring;
secondary non-response;
pharmaceutical care
- From:
Journal of Pharmaceutical Practice
2023;41(1):59-62
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of clinical pharmacists in individualized treatment and pharmaceutical care for a Crohn’s disease patient with non-response to infliximab. Methods The clinical pharmacist participated in the pharmaceutical care for a Crohn’s disease patient with hypoalbuminemia. Clinical pharmacists interpreted the blood concentration results of infliximab based on literature review, analyzed the pharmacokinetic process of drugs, and suggested that low serum albumin levels may cause the accelerated drug elimination and resulted in reduced drug concentration and secondary non-response. Results Clinical pharmacists assisted clinician adjusting the medication regimen and the patient recovered well after the new treatment plan. Conclusion With good understanding in medication pharmacokinetics and the blood test results, clinical pharmacists can help to solve the drug therapy related problems and establish an individual treatment plan to improve the safety and effectiveness of the biological medications.
